Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celldex Differentiated Immuno-Oncology Asset Ripe For Combos

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.

You may also be interested in...



Celldex To Fly Solo With Phase III Trial Of Brain Cancer Vaccine

All on its own, Celldex is gearing up to run a Phase III trial in the second half of 2011, testing its therapeutic cancer vaccine rindopepimut in newly diagnosed glioblastoma, after releasing positive results from ACT III, the last of three trials in its Phase II program.

A Sneak Peak At Pfizer’s Next-Generation ADC Pipeline

Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.

Stronger Together: Pfizer Highlights Newly Combined Oncology Portfolio

The company showcased its expanded cancer drug pipeline two months after completing the acquisition of Seagen last year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS005785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel